点击蓝字，关注我们核心观点事件：巨子生物发布2024年业绩公告。24年公司实现营收55.39亿元(yoy+57.2%)；实现经调整净利润21.52亿元（yoy+46.5%）。24年营收同比+57%，可复美表现亮眼、可丽金未来可期。2024年，公司实现收入55.39亿元，同比+57.2%，24H2实现营收29.99亿元，同比+56.36%。2024年分业务收入来看：1）专业皮肤护理产品，24年收入为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.